SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

04.08.2022 - – Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors Met Its Primary and All Key Secondary Endpoints – – Encouraging Preliminary Data from Phase 1/2 Study Evaluating Nirogacestat in Combination with ...

Related Keywords

Athens ,Attikír ,Greece ,Mirdametinib Monotherapy ,Samantha Hilson Sandler ,Saqib Islam ,Evangelos Terpos ,Development Agreement ,Hellenic Society Of Haematology ,School Of Medicine ,Drug Administration ,Cancer Therapy Evaluation Program ,Nasdaq ,Exchange Commission ,Pfizer ,Development Rd Expenses ,Springworks Therapeutics Inc ,Combination Therapy Studies ,Rare Oncology Indications ,Biomarker Defined Solid Tumors Continue ,Cohort Expansion Studies ,Combination Study ,Mirdametinib Planned ,Works Therapeutics ,Chief Executive Officer ,Business Highlights ,B Cell Maturation Antigen ,Precision Bioscience ,Keratopathy Visual Acuity ,Hellenic Society ,Clinical Therapeutics ,Kapodistrian University ,Beigene Sponsored Phase ,Springworks Sponsored Rd Day ,Cooperative Research ,Therapy Evaluation Program ,Carlos Alb ,Vice Chairman ,Chief Commercial Officer ,Loss Attributable ,Common Stockholders ,Forward Looking Statements ,Private Securities Litigation Reform Act ,Springwork Quarterly Report ,Consolidated Statements ,Working Capital ,